(Q26822908)

English

Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience

scientific article

In more languages

Statements

scholarly article

1 reference

Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience (English)

1 reference

1 reference

based on heuristic

inferred from title

object named as

Tine Dalby

2

0 references

Rachel Schneerson

5

object named as

Rachel Schneerson

1 reference

author name string

Birgit Thierry-Carstensen

1

1 reference

Michael A. Stevner

3

1 reference

John B. Robbins

4

1 reference

Birger Trollfors

6

1 reference

language of work or name

1 reference

publication date

25 October 2013

1 reference

1 reference

31

1 reference

45

1 reference

5178-91

1 reference

DTaP vaccines from north american vaccine (NAVA): composition and critical parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Rationale for pertussis booster vaccination throughout life in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Bordetella pertussis strains with increased toxin production associated with pertussis resurgence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Acellular pertussis vaccines and the role of pertactin and fimbriae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Pertussis vaccine: a critique

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A placebo-controlled trial of a pertussis-toxoid vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunogenicity and safety of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vac

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunization of children with pertussis toxoid decreases spread of pertussis within the family

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Pertussis after end of a mass vaccination project--end of the "vaccination honey-moon".

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Control of pertussis--lessons learnt from a 10-year surveillance programme in Sweden.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Itching nodules and hypersensitivity to aluminium after the use of adsorbed vaccines from SSI

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Persistent itching nodules after the fourth dose of diphtheria-tetanus toxoid vaccines without evidence of delayed hypersensitivity to aluminium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Vaccine related itching nodules and hypersensitivity to aluminium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunisation with aluminium-containing vaccine of a child with itching nodule following previous vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Late-onset vaccination-induced subcutaneous pseudolymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Comparison of culture and PCR for detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory conditions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Epidemiology of pertussis in Denmark: the impact of herd immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Duration of immunity against pertussis after natural infection or vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immunity to pertussis 5 years after booster immunization during adolescence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.034

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26822908&oldid=1986081781"